ArticleBMC bioinformatics2023
Cancer survival prediction by learning comprehensive deep feature representation for multiple types of genetic data.
Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Survival prediction of glioblastoma patients using machine learning and deep learning: a systematic review.BMC cancer · 2024Pooled it
- Survival prediction landscape: an in-depth systematic literature review on activities, methods, tools, diseases, and databases.Frontiers in artificial intelligence · 2024Pooled it
- A Neuroendocrine Differentiation-related Molecular Model for Prognosis Prediction in Prostate Cancer Patients.Current medicinal chemistry · 2026Article
- Artificial Intelligence-Driven Multi-Omics Approaches in Glioblastoma.International journal of molecular sciences · 2025Review
- Predicting survival in malignant glioma using artificial intelligence.European journal of medical research · 2025Review
- Multimodality Fusion Aspects of Medical Diagnosis: A Comprehensive Review.Bioengineering (Basel, Switzerland) · 2024Review
- Deep Learning for Genomics: From Early Neural Nets to Modern Large Language Models.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCancer is one of the leading death causes around the world. Accurate prediction of its survival time is significant, which can help clinicians make appropriate therapeutic schemes. Cancer data can be characterized by varied molecular features, clinical behaviors and morphological appearances. However, the cancer heterogeneity problem usually makes patient samples with different risks (i.e., short and long survival time) inseparable, thereby causing unsatisfactory prediction results. Clinical studies have shown that genetic data tends to contain more molecular biomarkers associated with cancer, and hence integrating multi-type genetic data may be a feasible way to deal with cancer heterogeneity. Although multi-type gene data have been used in the existing work, how to learn more effective features for cancer survival prediction has not been well studied.
resultsTo this end, we propose a deep learning approach to reduce the negative impact of cancer heterogeneity and improve the cancer survival prediction effect. It represents each type of genetic data as the shared and specific features, which can capture the consensus and complementary information among all types of data. We collect mRNA expression, DNA methylation and microRNA expression data for four cancers to conduct experiments.
conclusionsExperimental results demonstrate that our approach substantially outperforms established integrative methods and is effective for cancer survival prediction. AVAILABILITY AND IMPLEMENTATION: https://github.com/githyr/ComprehensiveSurvival .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.